The data shown on this page comes from Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries.
Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.
The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.
The 10th Edition of ISR’s CRO Quality Benchmarking Suite comes out this year. Here we take a look at how the CRO landscape has changed throughout the past decade.
Integration with eClinical software applications will drive IRT (interactive response technology) enhancements, but it is important to many study sponsors that IRT be delivered though companies that specialize in this technology.
What is the effect of a near-record volume of drug approvals? Just think about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities.
Using data from several market research reports, Industry Standard Research analyzed preferred provider arrangements across clinical development, eClinical, and contract manufacturing industries. Go to ISRreports.com/free-industry-resources to see the full infographic, which includes data for the contract manufacturing and eClinical markets.
Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries, has collected information from outsourcing decision makers via an online survey regarding their selection and evaluation of CROs.
Over the past several decades, the practice of outsourcing has evolved from transactional, client-vendor relationships where cost savings were the primary focus, to preferred provider relationships with pre-vetted companies to start up projects quickly and then to relationships more strategic in nature to gain access to technologies, skills, or expertise not possessed in-house.
Ameet Nathwani, M.D., EVP of Sanofi’s medical function, discusses digital health joint venture with Verily Life Sciences, and good places to look for digital health top talent.
In this preview of our July 2018 issue, the CEO of Sage Therapeutics, Jeff Jonas, M.D., elaborates on the company’s approach to developing small clinical trials.
Sage Therapeutics’ CEO Jeff Jonas, M.D., discusses what he means by a “return to the basics of science” at his company.
An op-ed regarding Pfizer’s drug-pricing actions, President Trump, and the potential impact on the biopharmaceutical industry’s image.
A review of buzzwords and phrases that should be used less in the world of business.